Sopharma AD Total Liabilities
Sopharma AD total liabilities. Based on the latest financial reports, Sopharma AD (SPH) has total liabilities worth zł1.04 Billion PLN (≈ $285.26 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how many days can Sopharma AD fund operations to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Sopharma AD (2011–2024)
Total liabilities of Sopharma AD from 2011 to 2024. This chart illustrates how Sopharma AD's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Sopharma AD to evaluate the company's liquid asset resilience ratio.
Sopharma AD Competitors by Total Liabilities
The table below lists competitors of Sopharma AD ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BM EUROP.UNSP.ADR /4
F:BMNU
|
Germany | €3.17 Billion |
|
Zhejiang Kaishan Compressor
SHE:300257
|
China | CN¥10.44 Billion |
|
Compania Cervecerias Unidas SA ADR
NYSE:CCU
|
USA | $1.91 Trillion |
|
GQG PARTNERS CDI/1/1
F:6P1
|
Germany | €50.29 Million |
|
Shriram Pistons & Rings Limited
NSE:SHRIPISTON
|
India | Rs31.34 Billion |
|
Aadhar Housing Finance Ltd
NSE:AADHARHFC
|
India | Rs181.89 Billion |
|
Encore Capital Group Inc
NASDAQ:ECPG
|
USA | $4.49 Billion |
|
National Energy Services Reunited Corp Ordinary Shares
NASDAQ:NESR
|
USA | $1.06 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Sopharma AD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Sopharma AD asset portfolio.
Liquidity & Leverage Metrics
Sopharma AD Total Liabilities Ratios Explained
Sopharma AD total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sopharma AD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sopharma AD (2011–2024)
The table below shows the annual total liabilities of Sopharma AD from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł953.18 Million ≈ $262.33 Million |
+25.33% |
| 2023-12-31 | zł760.54 Million ≈ $209.31 Million |
+41.45% |
| 2022-12-31 | zł537.67 Million ≈ $147.97 Million |
-1.55% |
| 2021-12-31 | zł546.11 Million ≈ $150.30 Million |
-19.16% |
| 2020-12-31 | zł675.52 Million ≈ $185.91 Million |
+12.68% |
| 2019-12-31 | zł599.50 Million ≈ $164.99 Million |
+19.40% |
| 2018-12-31 | zł502.07 Million ≈ $138.18 Million |
+5.12% |
| 2017-12-31 | zł477.62 Million ≈ $131.45 Million |
+29.79% |
| 2016-12-31 | zł368.00 Million ≈ $101.28 Million |
-2.64% |
| 2015-12-31 | zł377.99 Million ≈ $104.03 Million |
-2.01% |
| 2014-12-31 | zł385.73 Million ≈ $106.16 Million |
+4.25% |
| 2013-12-31 | zł370.01 Million ≈ $101.83 Million |
+4.50% |
| 2012-12-31 | zł354.06 Million ≈ $97.44 Million |
+13.93% |
| 2011-12-31 | zł310.78 Million ≈ $85.53 Million |
-- |
About Sopharma AD
Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral… Read more